KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Cash from Investing Activities: 2015-2025

Historic Cash from Investing Activities for CRISPR Therapeutics AG (CRSP) over the last 10 years, with Sep 2025 value amounting to -$119.2 million.

  • CRISPR Therapeutics AG's Cash from Investing Activities rose 26.22% to -$119.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $36.8 million, marking a year-over-year increase of 107.87%. This contributed to the annual value of -$280.5 million for FY2024, which is 174.87% down from last year.
  • CRISPR Therapeutics AG's Cash from Investing Activities amounted to -$119.2 million in Q3 2025, which was down 270.38% from $70.0 million recorded in Q2 2025.
  • Over the past 5 years, CRISPR Therapeutics AG's Cash from Investing Activities peaked at $216.9 million during Q2 2023, and registered a low of -$565.2 million during Q3 2021.
  • Its 3-year average for Cash from Investing Activities is $2.3 million, with a median of -$19.8 million in 2025.
  • As far as peak fluctuations go, CRISPR Therapeutics AG's Cash from Investing Activities crashed by 8,045.24% in 2021, and later skyrocketed by 486.87% in 2023.
  • CRISPR Therapeutics AG's Cash from Investing Activities (Quarterly) stood at -$8.7 million in 2021, then plummeted by 1,913.91% to -$175.5 million in 2022, then skyrocketed by 53.60% to -$81.5 million in 2023, then spiked by 229.93% to $105.8 million in 2024, then grew by 26.22% to -$119.2 million in 2025.
  • Its Cash from Investing Activities was -$119.2 million in Q3 2025, compared to $70.0 million in Q2 2025 and -$19.8 million in Q1 2025.